PharmaTalkRadio16 Jan 2023

Investment and Collaboration Strategies in Cell and Gene Therapy

This panel, first recorded at the 2022 IO360° Summit addressed: What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does that inform what people should be doing?How do we think about partnerships between organizations? Moderated by: Michael Polansky, CEO, Parker Group Panelists: Mark Bonyhadi, PhD, Senior Advisor, Qiming Venture PartnersElaine Cheung, SVP, Corporate Strategy & Business Development, Lyell ImmunopharmaArjun Goyal, MD, MPhil, MBA, Co-founder and Managing Director, Vida Ventures Learn more about the IO360° Summit at www.io360summit.com

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(461)

Immuno-Oncology Debate 2024 on Solving Cancer’s Top Challenges

For more information, visit theconferenceforum.org

9 Dec 202438min

CMO Misunderstandings about Clinical Operations and How to Improve

Many of the clinical trial delays and recruitment challenges in today's industry can be attributed to decisions made while designing the protocol and in the outsourcing strategy. Bringing clinical ope...

5 Dec 202433min

How Roche is Maximizing the Impact of Patient Insights in Early Development

For more information, go to theconferenceforum.org

3 Dec 202419min

Designing and Developing Drug Delivery for Lower and Middle-Income Countries

This podcast features a panel discussion on desgining and developing drug delivery and devices for LMICs with representatives from Gilead Sciences, the Bill & Melinda Gates Foundation, ApiJect and Abb...

21 Nov 202442min